Opinion Pieces

We can end the HIV epidemic–but Congress must act

Imagine if Congress, with one simple action, could help end a 40-year-old epidemic, erase some of the racial inequities in healthcare, and save money in the process. That may sound too good to be true. But lawmakers can do it if they fund expanding access programs to a highly effective HIV drug in the 2023 spending bill.

read more

Congress: Fund PrEP to end the HIV epidemic

As the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies considers this week what programs to fund in the 2023 budget, many public health concerns will demand their attention. One funding decision that would aim to end HIV — and that goal can be achieved — would also provide long-term benefits for the entire health care system. HIV continues to infect thousands of Americans each year, many of them gay men, even though an effective prevention tool known as pre-exposure prophylaxis (PrEP) is available. PrEP, which lowers the risk of contracting HIV by 99%, was first approved by the FDA in 2012 as a daily pill and is now available in a superior form as an every-other-month injection.

read more

Don’t compound tragic effect of COVID-19 on HIV

The silent tragedy of the COVID-19 pandemic is its devastating impact on people with other health conditions. For those illnesses, declining attention has persisted even as the threat of COVID-19 is declining. HIV provides a striking example of the setback — and how the effects are looming in the shadows. In December, President Biden set a goal of reducing new HIV infections to just 3,000 a year by 2030, a decline of more than 90 percent from current levels. That goal is achievable as long as Congress and the administration are putting the right policies in place and people can access and afford their medications.

read more

Prepare for the end of the HIV/AIDS epidemic

The end of the HIV/AIDS epidemic in the United States could soon be in sight. While we don’t yet have an HIV vaccine, we have drugs that are nearly 100% effective in preventing people from contracting HIV. These medicines are the cornerstone of a prevention approach called pre-exposure prophylaxis, or PREP. And since the start of 2021, PrEP drugs are supposed to be available at no out-of-pocket cost to most patients with private insurance. Yet obstacles stand in the way of implementing this highly effective prevention tool. These include awareness, stigma, and cost–yes, cost, despite the legal requirement that these drugs be provided free to patients. We must push forward on all these fronts to eliminate this virus once for all.

read more

Pin It on Pinterest